M
Melanie E Powell
Researcher at Barts Health NHS Trust
Publications - 58
Citations - 3993
Melanie E Powell is an academic researcher from Barts Health NHS Trust. The author has contributed to research in topics: Endometrial cancer & Medicine. The author has an hindex of 21, co-authored 45 publications receiving 2573 citations. Previous affiliations of Melanie E Powell include National Health Service & St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Dionyssios Katsaros,Paul Bessette,Christine Haie-Meder,Petronella B. Ottevanger,Jonathan A. Ledermann,Pearly Khaw,Alessandro Colombo,Anthony Fyles,Marie Helene Baron,Ina M. Jürgenliemk-Schulz,Henry C Kitchener,Hans W. Nijman,G. Wilson,Susan Brooks,Silvestro Carinelli,Diane Provencher,Chantal Hanzen,Ludy C.H.W. Lutgens,Vincent T.H.B.M. Smit,Naveena Singh,V. Do,Romerai D'Amico,Remi A. Nout,Amanda Feeney,Karen W Verhoeven-Adema,Hein Putter,Carien L. Creutzberg,Mary McCormack,Karen Whitmarsh,Rozenn Allerton,Deborah Gregory,P. Symonds,Peter Hoskin,Madhavi Adusumalli,Anjana Anand,Robert Wade,Alexandra J. Stewart,Wendy Taylor,Roy F.P.M. Kruitwagen,Harry Hollema,Elizabeth Pras,An Snyers,Lukas J.A. Stalpers,Jan J. Jobsen,Annerie Slot,Jan Willem M. Mens,Tanja C. Stam,Baukelien Van Triest,Elzbieta M. Van der Steen Banasik,Karin A.J. De Winter,Michael A. Quinn,Ilka Kolodziej,Jan Pyman,Carol Johnson,Anne Capp,Roldano Fossati,Sergio Gribaudo,Andrea Lissoni,Annamaria Ferrero,Grazia Artioli,Cathy Davidson,C. Meg McLachlin,Prafull Ghatage,Paula V.C. Rittenberg,Luis Souhami,Gillian Thomas,Pierre Duvillard,Dominique Berton-Rigaud,Nicole Tubiana-Mathieu +71 more
TL;DR: Adjuvant chemotherapy given during and after radiotherapy for high-risk endometrial cancer did not improve 5-year overall survival, although it did increase failure-free survival.
Journal ArticleDOI
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Alicia Leon-Castillo,Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Helen Mackay,Alexandra Leary,Hans W. Nijman,Hans W. Nijman,Naveena Singh,Pamela M. Pollock,Paul Bessette,Anthony Fyles,Christine Haie-Meder,Vincent T.H.B.M. Smit,Richard J. Edmondson,Hein Putter,Henry C Kitchener,Emma J Crosbie,Marco de Bruyn,Remi A. Nout,Nanda Horeweg,Carien L. Creutzberg,Tjalling Bosse +22 more
TL;DR: Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type.
Journal ArticleDOI
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Ellen Stelloo,Tjalling Bosse,Remi A. Nout,Helen Mackay,David N. Church,Hans W. Nijman,Alexandra Leary,Richard J. Edmondson,Melanie E Powell,Emma J Crosbie,Henry C Kitchener,Linda Mileshkin,Pamela M. Pollock,Vincent T.H.B.M. Smit,Carien L. Creutzberg +14 more
TL;DR: In this article, the authors investigated whether molecular analysis can be used to refine risk assessment, direct adjuvant therapy, and identify actionable alterations in high-risk endometrial cancer.
Journal ArticleDOI
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Dionyssios Katsaros,Paul Bessette,Christine Haie-Meder,Petronella B. Ottevanger,Jonathan A. Ledermann,Pearly Khaw,Romerai D'Amico,Anthony Fyles,Marie-Helene Baron,Ina M. Jürgenliemk-Schulz,Henry C Kitchener,Hans W. Nijman,G. Wilson,Susan Brooks,Sergio Gribaudo,Diane Provencher,Chantal Hanzen,Roy F.P.M. Kruitwagen,Vincent T.H.B.M. Smit,Naveena Singh,V. Do,Andrea Lissoni,Remi A. Nout,Amanda Feeney,Karen W Verhoeven-Adema,Hein Putter,Carien L. Creutzberg,M McCormack,K Whitmarsh,R Allerton,Deborah Gregory,P. Symonds,Peter Hoskin,M Adusumalli,Anjana Anand,R Wade,Alexandra J. Stewart,W Taylor,L.C.H.W. Lutgens,Harmen Hollema,Elisabeth Pras,An Snyers,GH Westerveld,J.J. Jobsen,Annerie Slot,J.W.M. Mens,Tanja C. Stam,B. van Triest,E. Van der Steen-Banasik,Kaj De Winter,Michael A. Quinn,Ilka Kolodziej,Jan Pyman,Colin D. Johnson,Anne Capp,Roldano Fossati,Alessandro Colombo,Silvestro Carinelli,Annamaria Ferrero,G Artioli,C Davidson,C M McLachlin,Prafull Ghatage,Pvc Rittenberg,Luis Souhami,Gillian Thomas,Pierre Duvillard,Dominique Berton-Rigaud,Nicole Tubiana-Mathieu +71 more
TL;DR: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer and did a post-hoc survival analysis to investigate patterns of recurrence.